Fortrea Holdings (FTRE) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$2.7B

Revenue (quarter)

$678.2M

Revenue growth (year over year)

−4.52%

Gross profit (trailing twelve months)

$516.6M

Gross margin

19.30%

Net income (trailing twelve months)

−$85.2M

Net income (quarter)

−$13.2M

Net income growth (year over year)

+96.48%

Net margin

−3.18%

Return on equity

−15.30%

EPS (trailing twelve months)

−$0.83

Book value per share

$5.51

P/E (trailing twelve months)

—

Price to book

3.80

Debt to assets

80.69%

Payout ratio

—

Dividend yield

—

Company profile

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

• Is Fortrea Holdings (FTRE) profitable?

  No. Fortrea Holdings reported a net loss of $85.2M over the trailing twelve months.

• How much revenue does Fortrea Holdings (FTRE) make?

  Fortrea Holdings generated $2.7B in revenue over the trailing twelve months, down 4.52% year over year.

• How do I buy stock in Fortrea Holdings (FTRE)?

  FTRE trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.